Feb 5 (Reuters) - Kyowa Kirin Co Ltd 4151.T:
KURA ONCOLOGY AND KYOWA KIRIN ANNOUNCE POSITIVE ZIFTOMENIB MONOTHERAPY REGISTRATIONAL TRIAL AND POSITIVE FDA FEEDBACK FOR UPCOMING FRONTLINE COMBINATION TRIAL DESIGNS
KURA ONCOLOGY INC: NDA SUBMISSION FOR ZIFTOMENIB ON TRACK FOR 2Q 2025
KURA ONCOLOGY INC: KOMET-017-IC AND NIC PHASE 3 TRIALS EXPECTED TO INITIATE IN 2H 2025
Source text: ID:nGNX4xK0s3
Further company coverage: 4151.T